|
An Overview
The Division of Cancer Immunotherapeutics and Tumor Immunology (CITI) is led by City of Hope's preeminent researchers and physicians, CITI's chair is Andrew Raubitschek, M.D., with Michael Jensen, M.D. as the Associate Chair, and Stephen Forman, M.D., as the Director of Clinical Research.
Immunotherapy, a powerful weapon against cancer because of its potential to exploit the body's natural defenses against infection, has been called the "fourth modality" of cancer treatment by the American Cancer Society. We want to make it a primary cure.
Currently, T-cell therapy and radioimmunotherapy offer renewed hope to people who have exhausted other treatment options. They are also effective for eliminating microscopic residual disease which can lead to cancer recurrence, even after chemotherapy, radiation therapy and surgery have been successful. The goal of CITI is to one day advance immunotherapeutic cures that will eliminate these more debilitating forms of treatment.
|